Price Chart

DATE TIME TYPE PERIOD REPORTED
EPS
ESTIMATED
EPS
SURPRISE
02/23/2022* -- Results Q4 2021 -- 3.64 --
02/23/2022* 16:30 EST Earnings Call Q4 2021 -- -- --
11/09/2021 -- Results Q3 2021 4.20 3.31 26.71%
11/09/2021 16:30 EST Earnings Call Q3 2021 -- -- --
08/03/2021 -- Results Q2 2021 3.90 3.45 13.15%
08/03/2021 16:30 EST Earnings Call Q2 2021 -- -- --
05/04/2021 -- Results Q1 2021 3.92 3.73 4.98%
05/04/2021 16:30 EST Earnings Call Q1 2021 -- -- --
*Estimated Date/Time

Earnings

Next Report Date 02/23/2022
EPS Estimate Upgrade
Last Actual EPS Upgrade

Loading chart...
Last Report Date 11/09/2021
Beat/Miss Upgrade
Return Since 6.55%
Last FQE 09/30/2021
Next FQE 12/30/2021

Profile

Edit
Jazz Pharmaceuticals is an Ireland-domiciled biopharmaceutical firm focused primarily on treatments for sleeping disorders and oncology. Jazz has nine approved drugs across neuroscience and oncology indications; its portfolio includes Xyrem and Xywav for narcolepsy, Zepzelca for the treatment of metastatic small-cell lung cancer, Rylaze for acute lymphoblastic leukemia, and Vyxeos for acute myeloid leukemia. In May 2021, Jazz acquired GW Pharmaceuticals and gained its leading product, Epidiolex for the treatment of severe, rare forms of epilepsy.
URL http://www.jazzpharmaceuticals.com
Investor Relations URL http://investor.jazzpharma.com
HQ State/Province N/A
Sector Healthcare
Industry Biotechnology
Equity Style Small Cap/Value
Next Earnings Release Feb. 23, 2022
Last Earnings Release Nov. 09, 2021
Next Ex-Dividend Date N/A
Last Ex-Dividend Date N/A

Dividends

Dividend Per Share (TTM) --
2017
2018
2019
2020
2021
No data available
 
6.00%
4.00%
2.00%
 
Yield to Market 0.00
Yield to Sector 0.00
Yield to Industry 0.00
Last Dividend Amt. --
Dividend Frequency --
Last Ex-Dividend Date --
Yield (TTM) 0%
Forward Yield --
Payout Ratio 0.00%
Cash Payout Ratio 0.00%
Consistent Payer (5Y) No
Consistent Growth (5Y) No

Ownership

Insider Ownership Percentage Upgrade
Jul '20
Nov '20
Mar '21
 
80.00%
40.00%
10.00%
 

Short Interest

Short Interest Upgrade
Percent of Shares Outstanding Short Upgrade
Jul '20
Nov '20
Mar '21
 
80.00%
40.00%
10.00%
 

Total Returns Comparison

Edit comparables

Annual Total Returns Versus Peers

Edit comparables
Loading chart...
Name
2015
2016
2017
2018
2019
2020
2021
YTD
-14.15%
-22.43%
23.50%
-7.94%
20.43%
10.56%
-22.81%
10.39%
1.38%
11.96%
21.83%
-4.38%
31.49%
18.40%
28.71%
-4.84%
-15.11%
-73.10%
-52.94%
-5.81%
-35.75%
53.09%
-47.63%
-10.90%
-13.18%
-42.14%
5.59%
-55.08%
35.65%
-11.92%
-10.96%
2.31%
35.55%
-29.98%
-1.53%
-46.08%
-30.87%
-2.21%
16.59%
7.48%
--
--
--
--
-10.18%
-78.02%
-60.38%
-4.29%
As of January 19, 2022.

Profile

Edit
Jazz Pharmaceuticals is an Ireland-domiciled biopharmaceutical firm focused primarily on treatments for sleeping disorders and oncology. Jazz has nine approved drugs across neuroscience and oncology indications; its portfolio includes Xyrem and Xywav for narcolepsy, Zepzelca for the treatment of metastatic small-cell lung cancer, Rylaze for acute lymphoblastic leukemia, and Vyxeos for acute myeloid leukemia. In May 2021, Jazz acquired GW Pharmaceuticals and gained its leading product, Epidiolex for the treatment of severe, rare forms of epilepsy.
URL http://www.jazzpharmaceuticals.com
Investor Relations URL http://investor.jazzpharma.com
HQ State/Province N/A
Sector Healthcare
Industry Biotechnology
Equity Style Small Cap/Value
Next Earnings Release Feb. 23, 2022
Last Earnings Release Nov. 09, 2021
Next Ex-Dividend Date N/A
Last Ex-Dividend Date N/A

Ownership

Insider Ownership Percentage Upgrade
Jul '20
Nov '20
Mar '21
 
80.00%
40.00%
10.00%
 

Short Interest

Short Interest Upgrade
Percent of Shares Outstanding Short Upgrade
Jul '20
Nov '20
Mar '21
 
80.00%
40.00%
10.00%
 

Top Fund Holders

Symbol Dollars Invested % Weight
HMMJ.TO 33.45M USD 11.79%
MJ 30.17M USD 3.66%
PJP 12.54M USD 3.66%
PPH 11.25M USD 2.86%
RBF1542 16.15M USD 2.35%
FRBRX 26.66M USD 2.32%
PGVFX 9.414M USD 1.87%
QFVOX 72.49M USD 1.67%
PEIRX 23.33M USD 1.30%
IJJ 63.60M USD 0.72%
VMFVX 5.984M USD 0.64%
XT 24.34M USD 0.61%

Top Portfolio Holders

0 of 0

Other Resources

Whale Wisdom 13F Filings
Seeking Alpha Call Transcripts
Morningstar Insider Trading
Nasdaq Institutional Ownership
Nasdaq Option Chain
SEC SEC Filings
Stocktwits JAZZ Tweets